查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1339169

子宫肌瘤治疗市场、份额、规模、趋势、行业分析报告:按药物类别、按药物类型、按最终用途、按地区、按细分市场、预测，2023-2032 年

Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, & Segment Forecasts, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2032年，全球子宫肌瘤治疗市场规模预计将达到108.3亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

子宫肌瘤（UF）是影响育龄妇女的常见疾病，经血过多是最常见的症状之一。 GnRH 拮抗剂和释放孕激素的子宫内避孕器等新型药物的开发为患有子宫肌瘤的女性提供了更有效的治疗选择。 这些因素，加上意识和诊断的提高，正在推动市场成长。

根据 IntechOpen 的分析，月经过多是 UF 最常见的症状，每年影响近 140 万名女性。 此外，约 60% 的女性报告有体力活动减少和生活品质下降等症状。

对更有效、更安全的子宫肌瘤治疗方法的需求不断增加，这是该领域研究和开发的驱动力。 随着研究活动资金的增加，更先进和创新疗法的开发预计将进一步推动市场成长。 此外，个人化医疗和精准治疗的发展也有望推动市场成长，因为它有可能为个别患者提供更有针对性和更有效的治疗选择。

最近，妇女健康研究协会(SWHR) 批准并重新提出了《2021 年斯蒂芬妮.塔布斯.琼斯子宫肌瘤研究和教育法案》。希望这将资助和支持肌瘤研究并加速新疗法的开发。 此外，最近批准了几种 GnRH 拮抗剂（包括 myfenbrey）用于治疗与子宫肌瘤相关的严重出血，这可能会支持市场成长。

子宫肌瘤治疗市场报告重点

GnRH 拮抗剂部分由于其高效和有效的治疗选择预计将增长更快。

黏膜下子宫肌瘤市场占最大份额。 这主要是由于其高盛行率和严重性。 常见于亚洲女性

由于药物和其他联合疗法易于取得，零售药局市场预计将占据很大份额

由于美国的高盛行率、医疗设施的可用性以及个人对其有害影响的高度认识，预计北美将出现更大的增长。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球子宫肌瘤治疗市场洞察

  • 子宫肌瘤治疗市场 - 最终用途概况
  • 子宫肌瘤治疗市场动态
    • 推动者和机会
      • 子宫肌瘤患者的人增加
      • 努力提高人们对子宫肌瘤诊断和治疗的认识
    • 抑制因素和挑战
      • 严格的监理框架
  • PESTEL 分析
  • 子宫肌瘤治疗市场最终用途趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章全球子宫肌瘤治疗市场（依药物类别）

  • 主要发现
  • 简介
  • 促性腺激素释放激素 (GnRH) 激动剂
  • 促性腺激素释放激素 (GnRH) 拮抗剂
  • 释放黄体素的子宫内避孕器 (IUD) 和避孕药具
  • 非荷尔蒙药物
  • 其他

第 6 章全球子宫肌瘤治疗市场（依药物类型）

  • 主要发现
  • 简介
  • 浆膜下肌瘤
  • 壁内肌瘤
  • 黏膜下肌瘤
  • 带蒂肌瘤

第 7 章全球子宫肌瘤治疗市场，依最终用途划分

  • 主要发现
  • 简介
  • 医院药房
  • 零售药局
  • 其他

第 8 章全球子宫肌瘤治疗市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年子宫肌瘤治疗市场评估（按地区）
  • 子宫肌瘤治疗市场 - 北美
    • 北美:子宫肌瘤治疗市场，依药物类别，2019-2032 年
    • 北美:子宫肌瘤治疗市场（以最终用途），2019-2032 年
    • 北美:子宫肌瘤治疗市场（以药物类型），2019-2032 年
    • 子宫肌瘤治疗市场 - 美国
    • 子宫肌瘤治疗市场 - 加拿大
  • 子宫肌瘤治疗市场 - 欧洲
    • 欧洲:子宫肌瘤治疗市场，依药物类别，2019-2032 年
    • 欧洲:子宫肌瘤治疗市场（以最终用途），2019-2032 年
    • 欧洲:子宫肌瘤治疗市场，依药物类型，2019-2032 年
    • 子宫肌瘤治疗市场 - 英国
    • 子宫肌瘤治疗市场 - 法国
    • 子宫肌瘤治疗市场 - 德国
    • 子宫肌瘤治疗市场 - 义大利
    • 子宫肌瘤治疗市场 - 西班牙
    • 子宫肌瘤治疗市场 - 荷兰
    • 子宫肌瘤治疗市场 - 俄罗斯
  • 子宫肌瘤治疗市场 - 亚太地区
    • 亚太地区:子宫肌瘤治疗市场，依药物类别，2019-2032 年
    • 亚太地区:子宫肌瘤治疗市场（依最终用途），2019-2032 年
    • 亚太地区:子宫肌瘤药物市场（依药物类型），2019-2032 年
    • 子宫肌瘤治疗市场 - 中国
    • 子宫肌瘤治疗市场 - 印度
    • 子宫肌瘤治疗市场 - 马来西亚
    • 子宫肌瘤治疗市场 - 日本
    • 子宫肌瘤治疗市场 - 印度尼西亚
    • 子宫肌瘤治疗市场 - 韩国
  • 子宫肌瘤治疗市场 - 中东和非洲
    • 中东和非洲:子宫肌瘤治疗市场（按药物类别），2019-2032 年
    • 中东和非洲:子宫肌瘤治疗市场（以最终用途），2019-2032 年
    • 中东和非洲:子宫肌瘤治疗市场（按药物类型），2019-2032 年
    • 子宫肌瘤治疗市场 - 沙乌地阿拉伯
    • 子宫肌瘤治疗市场 - 阿联酋
    • 子宫肌瘤治疗市场 - 以色列
    • 子宫肌瘤治疗市场 - 南非
  • 子宫肌瘤治疗市场 - 拉丁美洲
    • 拉丁美洲:子宫肌瘤治疗市场，依药物类别，2019-2032 年
    • 拉丁美洲:子宫肌瘤治疗市场（以最终用途），2019-2032 年
    • 拉丁美洲:子宫肌瘤治疗市场，依药物类型，2019-2032 年
    • 子宫肌瘤治疗市场 - 墨西哥
    • 子宫肌瘤治疗市场 - 巴西
    • 子宫肌瘤治疗市场 - 阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • Myovant Sciences
  • Pfizer
  • Abbvie
  • Ferring
  • AstraZeneca
  • Bayer
  • Amring Pharmaceuticals
  • Watson Pharma
Product Code: PM3549

The global uterine fibroid treatment market size is expected to reach USD 10.83 billion by 2032, according to a new study by Polaris Market Research. The report "Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Uterine fibroids (UF) are a common condition affecting women of reproductive age, with heavy menstrual bleeding being one of the most common symptoms. The development of novel drugs, such as GnRH antagonists and progestin-releasing IUDs, has provided more effective treatment options for women with uterine fibroids. These factors, along with increased awareness and diagnosis, are driving the growth of the market.

As per the analysis done by the IntechOpen, excessive menstrual bleeding is the most common symptom in the UF, affecting almost 1.4 Mn women each year. Moreover, around 60 percent of the women have reported the symptoms of physical in-activity and quality of life.

Demand for more effective and safer treatment options for uterine fibroids is increasing, and this is driving research and development efforts in the field. With increased funding for research activities, the development of more advanced and innovative treatment options is expected, which will further drive the growth of the market. Additionally, the development of personalized medicine and precision therapies is also expected to drive growth in the market, as these approaches may offer more targeted and effective treatment options for individual patients.

The recent endorsement and reintroduction of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 by the Society for Women's Health Research (SWHR) will provide funding and support for research on uterine fibroids, which is expected to boost the development of novel treatments. Additionally, the recent approval of multiple GnRH antagonists such as Myfembree for the treatment of heavy bleeding associated with fibroids will also drive the market growth.

Uterine Fibroids Treatment Market Report Highlights

GnRH antagonists' segment is anticipated to witness faster growth owing to its high efficacy and effective treatment option.

Sub-mucosal fibroids segment accounted for the larger market share. This is primarily due its high prevalence rate and severity. It is most common among Asian women

Retail pharmacies segment expected to garner substantial share, owing to easy availability of drugs and other combination therapies

North America is expected to grow larger revenue, owing to high prevalence rate in the US. presence of better medical facilities, and awareness among individuals about ill effects.

The global players include: Myovant Sciences, Pfizer, Abbvie, Ferring, AstraZeneca, Bayer, Amring Pharmaceuticals, and Watson Pharma.

Polaris Market Research has segmented the uterine fibroids treatment market report based on drug type, drug class, end use, and region:

Uterine Fibroids Treatment, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroids Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Gonadotropin-releasing Hormone (GnRH) Agonists
  • Gonadotropin-releasing Hormone (GnRH) Antagonists
  • Progestin-releasing Intrauterine Device (IUD) & Contraceptives
  • Non-hormonal Medications
  • Others

Uterine Fibroids Treatment, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroids Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data End Uses
    • 3.2.1. Primary End Uses
    • 3.2.2. Secondary End Uses

4. Global Uterine Fibroid Treatment Market Insights

  • 4.1. Uterine Fibroid Treatment Market - End Use Snapshot
  • 4.2. Uterine Fibroid Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Population Base For Uterine Fibroids Patients
      • 4.2.1.2. Growing Awareness Initiatives Related To Uterine Fibroids Diagnosis And Treatment
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Stringent Regulatory Framework
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Uterine Fibroid Treatment Market End Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Uterine Fibroid Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. Gonadotropin-releasing Hormone (GnRH) Agonists
    • 5.3.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Agonists, by Region, 2019-2032 (USD Billion)
  • 5.4. Gonadotropin-releasing Hormone (GnRH) Antagonists
    • 5.4.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Antagonists, by Region, 2019-2032 (USD Billion)
  • 5.5. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
    • 5.5.1. Global Uterine Fibroid Treatment Market, by Progestin-releasing Intrauterine Device (IUD) & Contraceptives, by Region, 2019-2032 (USD Billion)
  • 5.6. Non-hormonal Medications
    • 5.6.1. Global Uterine Fibroid Treatment Market, by Non-hormonal Medications, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Uterine Fibroid Treatment Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Uterine Fibroid Treatment Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 6.3. Subserosal Fibroids
    • 6.3.1. Global Uterine Fibroid Treatment Market, by Subserosal Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.4. Intramural Fibroids
    • 6.4.1. Global Uterine Fibroid Treatment Market, by Intramural Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.5. Submucosal Fibroids
    • 6.5.1. Global Uterine Fibroid Treatment Market, by Submucosal Fibroids, by Region, 2019-2032 (USD Billion)
  • 6.6. Pedunculated Fibroids
    • 6.6.1. Global Uterine Fibroid Treatment Market, by Pedunculated Fibroids, by Region, 2019-2032 (USD Billion)

7. Global Uterine Fibroid Treatment Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Uterine Fibroid Treatment Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Uterine Fibroid Treatment Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Uterine Fibroid Treatment Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Uterine Fibroid Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Uterine Fibroid Treatment Market - North America
    • 8.3.1. North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4. Uterine Fibroid Treatment Market - U.S.
      • 8.3.4.1. U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5. Uterine Fibroid Treatment Market - Canada
      • 8.3.5.1. Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4. Uterine Fibroid Treatment Market - Europe
    • 8.4.1. Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4. Uterine Fibroid Treatment Market - UK
      • 8.4.4.1. UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5. Uterine Fibroid Treatment Market - France
      • 8.4.5.1. France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6. Uterine Fibroid Treatment Market - Germany
      • 8.4.6.1. Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7. Uterine Fibroid Treatment Market - Italy
      • 8.4.7.1. Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8. Uterine Fibroid Treatment Market - Spain
      • 8.4.8.1. Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9. Uterine Fibroid Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10. Uterine Fibroid Treatment Market - Russia
      • 8.4.10.1. Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5. Uterine Fibroid Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4. Uterine Fibroid Treatment Market - China
      • 8.5.4.1. China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5. Uterine Fibroid Treatment Market - India
      • 8.5.5.1. India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6. Uterine Fibroid Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7. Uterine Fibroid Treatment Market - Japan
      • 8.5.7.1. Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8. Uterine Fibroid Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9. Uterine Fibroid Treatment Market - South Korea
      • 8.5.9.1. South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6. Uterine Fibroid Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4. Uterine Fibroid Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5. Uterine Fibroid Treatment Market - UAE
      • 8.6.5.1. UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6. Uterine Fibroid Treatment Market - Israel
      • 8.6.6.1. Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7. Uterine Fibroid Treatment Market - South Africa
      • 8.6.7.1. South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7. Uterine Fibroid Treatment Market - Latin America
    • 8.7.1. Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4. Uterine Fibroid Treatment Market - Mexico
      • 8.7.4.1. Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5. Uterine Fibroid Treatment Market - Brazil
      • 8.7.5.1. Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6. Uterine Fibroid Treatment Market - Argentina
      • 8.7.6.1. Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Myovant Sciences
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Drug Class Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Drug Class Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Abbvie
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Drug Class Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Ferring
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Drug Class Benchmarking
    • 10.4.4. Recent Development
  • 10.5. AstraZeneca
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Drug Class Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Bayer
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Drug Class Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Amring Pharmaceuticals
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Drug Class Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Watson Pharma
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Drug Class Benchmarking
    • 10.8.4. Recent Development

List of Tables

  • Table 1 Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 3 Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 4 Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 7 North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 17 UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 19 UK: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 20 France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 22 France: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 41 China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 43 China: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 44 India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 46 India: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Uterine Fibroid Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Type
  • Figure 7. Global Uterine Fibroid Treatment Market, by Drug Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Uterine Fibroid Treatment Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Uterine Fibroid Treatment Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 12. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Uterine Fibroid Treatment Market